Ctpe anthrax AV7909 boost evaluation and antigen-sparing trial (ABEAST)

Active Awarded Last action

Contract number
75A50122F33004
Awardee
Awarding agency
Obligated
$10,320,205

Award facts

Contract value 79% obligated
  • $10,320,205.00 Current, with exercised options
  • $13,130,463.00 Potential, with all options
Completion date 83% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Hinckley, OH 44233, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00013 $0
Exercise an Option P00012 $705,645
Other Administrative Action P00011 $0
Other Administrative Action P00010 $0
Other Administrative Action P00009 $0
Other Administrative Action P00008 $0
Other Administrative Action P00007 $0
Other Administrative Action P00006 $0
Other Administrative Action P00005 $0
Other Administrative Action P00004 $0
Other Administrative Action P00003 $0
Other Administrative Action P00002 · Icon- abeast study $0
Other Administrative Action P00001 · The purpose of this modification is to revise article E. Deliverables/schedule item #1: kickoff meeting due date from: within 30 calendar days from award to:… $0
Original award $9,614,560
Show all 14

About this award

Written by GovTribe AI ·

The U.S. Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded a $13.1 million delivery order to Icon Government and Public Health Solutions, Inc. on September 13, 2022, for the CTPE Anthrax AV7909 Boost Evaluation and Antigen-Sparing Trial (ABEAST). This cost-plus-fixed-fee contract, with an ultimate completion date of September 12, 2027, will be performed in Hinckley, Ohio. The award represents no set-aside designation and was issued under open competition. Icon Government and Public Health Solutions, a Pennsylvania-based, foreign-owned firm specializing in clinical research services, will provide comprehensive support for this anthrax vaccine clinical trial, leveraging its extensive experience in protocol development, study execution, data management, and regulatory submissions across federal medical countermeasure development programs.

This delivery order builds upon Icon's substantial portfolio of federal clinical research contracts, including a $550 million Clinical Trials Planning and Execution IDIQ vehicle with ASPR that facilitates rapid task order issuance. The company has demonstrated significant capacity in executing complex clinical trials for the Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID), and Department of Defense. The ABEAST study aligns with ASPR's broader mission to advance medical countermeasures for public health emergencies and biodefense threats, with Icon's contract supporting critical research on optimizing anthrax vaccine efficacy and antigen utilization.

Quick answers

Who was awarded contract 75A50122F33004?

75A50122F33004 was awarded to Icon Government And Public Health Solutions, Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 13, 2022.

How much is contract 75A50122F33004 worth?

The government has obligated $10,320,205 on 75A50122F33004. Its potential value, with all options, is $13,130,463.

Is contract 75A50122F33004 an order under another contract?

Yes. 75A50122F33004 is a delivery order under 75A50120D00017, an indefinite delivery contract.

Was contract 75A50122F33004 competed?

The extent of competition for 75A50122F33004 was full and open competition.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login